Russia to control production of generics of foreign drugs under patent protection

Russia will allow domestic drugmakers to develop generics of original foreign drugs under patent protection only in case of exodus of their producers from the Russian market.

So far, these have been confirmed by members of the Russian Parliament (State Duma) and Vadim Kukava, executive director of the Association of Pharmaceutical Companies (Infarma), a trade association, which unites some global drugmakers, operating in the Russian market, reports The Pharma Letter’s local correspondent.

According to Mr Kukava, as of now there are no such prerequisites. “We see certain risks there. But in response to my public question in the Duma, it was once again confirmed that this mechanism will be applied when and if Western manufacturers begin to leave the market,” he said during the “Pharma and healthcare: tasks of the new time” conference, organized by the Russian business paper Kommersant.